ABSTRACT
Documentation in scientific literature is not available on prospective evaluation of the efficiency of the unlock measure related to COVID-19 transmission change points in India, projecting the infected population, planning suitable measures related to future interventions and lifting of restrictions so that the economic settings are not damaged beyond repair. We have applied SIR model and Bayesian approach combined with Monte Carlo Markov algorithms on the Indian COVID-19 daily new infected cases from 1 August 2020 to 30 September 2020. We showed that the COVID-19 epidemic declined after implementing unlock-4 measure and the identified change-points were consistent with the timelines of announced unlock-3 and unlock-4 measure, on 1 August 2020 and 1 September 2020, respectively, effectiveness of which were quantified as the change in both effective transmission rates (100% reduction) and the basic reproduction number attaining 1, implying measures taken to control and mitigate the COVID-19 epidemic in India managed to flatten and recede the epidemic curve.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding for this specific work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable (Details of the method are mentioned in the manuscript)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in this study are publicly available, and are preserved with the authors in this connection.
